Phase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer: Double tubulin targeting: ORIGINAL ARTICLE

Internal Medicine Journal

Volumn 40, Issue 3, 2010, Pages 201-208

  Sewak, S ^a   Kosmider, S ^b   Ganju, V ^b   Woollett, A ^a   Yeow, E G ^a   Le, B ^b   Henry, M ^b   Debrincat, M A ^a   Bell, R ^a  

^a GEELONG HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Hormone refractory prostate cancer; Paclitaxel; Phase 2 clinical trial; Prostate cancer; Vinorelbine

Indexed keywords

NAVELBINE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; TUBULIN;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; HUMAN; INFECTION; LETHARGY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; SENSORY NEUROPATHY; SEPSIS; SOMNOLENCE; VOMITING;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUBULIN; VINBLASTINE;

EID: 77949642046     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2009.01987.x     Document Type: Article

References (21)

1. Giles G, Thursfield V. Canstat Cancer Epidemiology Centre, The Cancer Council Victoria cited 2004]. Available from URL: http://www.cancervic.org.au
2. Rosenthal MA. Management of metastatic prostate cancer. Med J Aust 1998 169 : 46 50.
3. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004 351 : 1513 1520.
4. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 351 : 1502 1512.
5. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003 21 : 1232 1237.
6. Binet S, Fellous A, Lataste H, Krikorian A, Couzinier JP, Meininger V. In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence. Semin Oncol 1989 16 (2 Suppl 4 5 8.
7. Vaughn D, Brown A, Harker W, Huh S, Miller G, Rinaldi D et al. Phase II evaluation of weekly paclitaxel and estramustine phosphate in androgen-independent prostate cancer. ASCO Annual Meeting 2003 22 : 402 (Abstract 1615).
8. Spencer CM, Faulds D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994 48 : 794 847.
9. de Souza P, Myers C. Synergy analysis of vinorelbine and paclitaxel in prostate cancer. Proc Am Ass Cancer Res 1998 39 : 586 (abstract 1986).
10. Trivedi C, Redman B, Flaherty LE, Kucuk O, Du W, Heilbrun LK et al. Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer 2000 89 : 431 436.
11. Abratt RP, Brune D, Dimopoulos MA, Kliment J, Breza J, Selvaggi FP et al. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Ann Oncol 2004 15 : 1613 1621.
12. Sewak S, Chachoua A, Hamilton A, Taneja S, Lee J, Utate M et al. A phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: triple tubulin targeting. Anticancer Drugs 2003 14 : 67 72.
13. Benson R, Hartley-Asp B. Mechanisms of action and clinical uses of estramustine. Cancer Invest 1990 8 : 375 380.
14. Fizazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymard JC et al. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 2007 8 : 994 1000.
15. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982 5 : 649 655.
16. Stockler MR, Osoba D, Corey P, Goodwin PJ, Tannock IF. Convergent discriminitive, and predictive validity of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) assessment and comparison with analogous scales from the EORTC QLQ-C30 and a trial-specific module. European Organisation for Research and Treatment of Cancer. Core quality of life questionnaire. J Clin Epidemiol 1999 52 : 653 666.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 92 : 205 216.
18. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999 17 : 3461 3467.
19. Goodin S, Rao KV, Kane M, Dave N, Capanna T, Doyle-Lindrud S et al. A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer. Cancer Chemother Pharmacol 2005 56 : 199 204.
20. Hahn NM, Marsh S, Fisher W, Langdon R, Zon R, Browning M et al. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clin Cancer Res 2006 12 (20 Pt 1 6094 6099.
21. Di Lorenzo G, Autorino R, Perdona S, De Laurentiis M, D'Armiento M, Cancello G et al. Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. Eur Urol 2007 52 : 1020 1027.